UPDATE: JP Morgan Cuts PT to $7 on Arena Pharmaceuticals on Belviq Launch Concerns
Posted on March 05, 2013 at 15:05 PM EST
JP Morgan maintained Arena Pharmaceuticals (NASDAQ: ARNA ) with a Neutral rating and lowered the price target from $8.00 to $7.00. JP Morgan commented, "We continue to see few signs that the early launch of Belviq will avoid the problems VVUS is currently experiencing with its weight loss drug, Qsymia